Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 324-336
DOI: 10.1111/dom.70195 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 15.10.2025. Verfasst von Phyo Than Htoo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Boehringer Ingelheim, American Diabetes Association, NIA NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Understanding the real‐world impact of treatment with empagliflozin and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) on healthcare resource utilization (HCRU) and costs could help inform clinical decision‐making and healthcare policy. Materials and Methods We conducted a comparative‐effectiveness cohort study comparing HCRU and costs following empagliflozin versus GLP‐1RA treatment in adults with type 2 diabetes (≥18 years) using US Medicare and commercial claims (08/2014–09/2019). We estimated rate ratios (RR) for HCRU outcomes using zero‐inflated negative binomial regression and cost differences per member per year (PMPY) using gamma regression after adjusting for 143 baseline covariates via propensity score matching.
Results
We identified 146,341 matched pairs across all databases. After matching, the rates of hospital days, hospitalizations, emergency department (ED) visits, and physician office visits were similar between treatments. Empagliflozin had lower rates of dispensed medication classes versus GLP‐1RA across most databases (RRs ranged from 0.91 to 0.95, RDs from −1246 to −709 per 1000 PY, reflecting varying degrees of precision). Total costs of care were lower with empagliflozin versus GLP‐1RA. PMPY ratios ranged from 0.93 to 0.97 and differences from −$1425 to −$847. Inpatient and outpatient costs were comparable between treatments. Empagliflozin had lower pharmacy costs than GLP‐1RA, mainly driven by glucose‐lowering medications (PMPY ratios ranging from 0.91 to 0.95; PMPY differences from −$799 to −$441).
Conclusions
Among adults with diabetes, empagliflozin was associated with similar rates of inpatient days, hospitalizations, ED, and office visits, with lower dispensed medication rates compared with GLP‐1RA. Empagliflozin initiators incurred lower total costs, driven by lower glucose‐lowering medication costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
- Global Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
ORCID-Profile: Phyo Than Htoo, Helen Tesfaye, Elisabetta Patorno
Förderung
- Boehringer Ingelheim
- American Diabetes Association
- NIA NIH HHS
- FDA HHS
- National Institute on Aging
- Food and Drug Administration
Zitieren
APA
Htoo, P. T., Tesfaye, H., Schneeweiss, S., Wexler, D. J., Glynn, R. J., DiCesare, E., Freedman, A., Schmedt, N., Shay, C., Paik, J. M., & Patorno, E. (2026). Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes. Diabetes, Obesity and Metabolism, 28(1), 324-336. https://doi.org/10.1111/dom.70195
Vancouver
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Glynn RJ, DiCesare E, et al. Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes. Diabetes, Obesity and Metabolism. 2026;28(1):324-336. doi:10.1111/dom.70195
BibTeX
@article{Htoo2026,
author = {Htoo, Phyo Than and Tesfaye, Helen and Schneeweiss, Sebastian and Wexler, Deborah J and Glynn, Robert J and DiCesare, Elyse and Freedman, Ariel and Schmedt, Niklas and Shay, Christina and Paik, Julie M and Patorno, Elisabetta},
title = {Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {1},
pages = {324--336},
doi = {10.1111/dom.70195}
}
EUVIMED